219 related articles for article (PubMed ID: 34614146)
1. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
[TBL] [Abstract][Full Text] [Related]
2. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
[TBL] [Abstract][Full Text] [Related]
3. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
4. Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.
Bitansky G; Avigdor A; Vasilev E; Zlotnick M; Ribakovsky E; Benjamini O; Nagler A; Kedmi M
Leuk Lymphoma; 2020 Nov; 61(11):2645-2651. PubMed ID: 32643497
[TBL] [Abstract][Full Text] [Related]
5. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA; Schär S; Hayoz S; Pirosa MC; Taverna C; Novak U; Kimby E; Ghielmini M; Zucca E
Br J Haematol; 2021 Mar; 192(6):1031-1034. PubMed ID: 32805081
[TBL] [Abstract][Full Text] [Related]
7. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
[TBL] [Abstract][Full Text] [Related]
8. External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse.
Boyne DJ; Chua N; Owen C; Joe-Uzuegbu O; Shakir H; Gogna P; Jarada TN; Brenner DR; Elia-Pacitti J; Ewara EM; Cheung WY
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e277-e285. PubMed ID: 37331847
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.
Gao F; Zhang T; Liu H; Li W; Liu X; Qiu L; Li L; Zhou S; Qian Z; Dong S; Zhao S; Wang X; Zhang H
Ann Hematol; 2022 Nov; 101(11):2383-2392. PubMed ID: 36029326
[TBL] [Abstract][Full Text] [Related]
10. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma.
Suzuki Y; Yano T; Suehiro Y; Iwasaki H; Hidaka M; Otsuka M; Sunami K; Ikeda H; Sawamura M; Ito T; Iida H; Nagai H
Int J Hematol; 2020 Dec; 112(6):817-824. PubMed ID: 32886278
[TBL] [Abstract][Full Text] [Related]
12. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
[TBL] [Abstract][Full Text] [Related]
13. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
[TBL] [Abstract][Full Text] [Related]
15. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract][Full Text] [Related]
16. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of POD24 in peripheral T-cell lymphoma.
Chen H; Ma R; Zhang Q; Lu F; Ma Y; Zhou J; Cao J; Qi K; Yan Z; Sang W; Zhu F; Sun H; Li D; Li Z; Cheng H; Xu K; Chen W
Hematology; 2024 Dec; 29(1):2304483. PubMed ID: 38251872
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
Cánovas A; Alonso JJ; Barreiro G; Aguirre C
Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
[TBL] [Abstract][Full Text] [Related]
19. How I treat early-relapsing follicular lymphoma.
Casulo C; Barr PM
Blood; 2019 Apr; 133(14):1540-1547. PubMed ID: 30700421
[TBL] [Abstract][Full Text] [Related]
20. The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma.
Hu J; Gao F; Zhao J; Song W; Wang Y; Zheng Y; Wang L; Han W; Ma L; Wang J; Bai M; Guan T; Xi Y; Zhang H; Qiu L; Su L
Front Oncol; 2023; 13():1090610. PubMed ID: 37427106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
